A Multicenter, Open, Randomized, 24 Weeks Study to Evaluate the Superiority of Glimepiride Over Sitagliptin for the Treatment of naive Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2010
At a glance
- Drugs Glimepiride; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SUMER
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 29 Nov 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 29 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.